Jane Street Group, LLC Argenx Se Call Options Transaction History

Jane Street Group, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$434.22 - $551.9 $1.78 Million - $2.26 Million	4,100 New	4,100 $2.22 Million
Q2 2022 Aug 16, 2022	SELL	$269.58 - $378.88 $7.41 Million - $10.4 Million	-27,500 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$254.45 - $351.06 $6.77 Million - $9.34 Million	26,600 Added 2955.56%	27,500 $8.67 Million
Q4 2021 Feb 15, 2022	SELL	$272.01 - $353.03 $8.79 Million - $11.4 Million	-32,300 Reduced 97.29%	900 $315,000
Q3 2021 Nov 16, 2021	SELL	$295.0 - $350.58 $1.98 Million - $2.35 Million	-6,700 Reduced 16.79%	33,200 $10 Million
Q2 2021 Aug 16, 2021	BUY	$257.11 - $319.92 $1.54 Million - $1.92 Million	6,000 Added 17.7%	39,900 $12 Million
Q1 2021 May 18, 2021	SELL	$268.3 - $380.31 $643,920 - $912,744	-2,400 Reduced 6.61%	33,900 $9.34 Million
Q4 2020 Feb 17, 2021	SELL	$248.13 - $308.36 $9.45 Million - $11.7 Million	-38,100 Reduced 51.21%	36,300 $10.7 Million
Q3 2020 Nov 17, 2020	BUY	$215.51 - $272.51 $2.89 Million - $3.65 Million	13,400 Added 21.97%	74,400 $19.5 Million
Q2 2020 Aug 17, 2020	BUY	$127.44 - $232.72 $7.77 Million - $14.2 Million	61,000 New	61,000 $13.7 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.